AMPE

Ampio Pharmaceuticals, Inc. [AMPE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AMPE Stock Summary

Top 10 Correlated Stocks

AMPE


In the News

09:15 28 Mar 2024 AMPE

Ampio Pharmaceuticals to Present at the Emerging Growth Conference

ENGLEWOOD, Colo. , Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A.

09:30 28 Mar 2024 AMPE

3 Biotech Stocks to Buy With Explosive Upside Potential

The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.

11:30 28 Mar 2024 AMPE

Which Strategies Are You Using With Penny Stocks in September?

Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?

04:20 28 Mar 2024 AMPE

Why These 3 Penny Stocks Are Climbing in Late April

Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:29 28 Mar 2024 AMPE

Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial

Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.  In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in.

08:17 28 Mar 2024 AMPE

New Strong Sell Stocks for April 7th

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

08:17 28 Mar 2024 AMPE

New Strong Sell Stocks for April 1st

AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.

06:41 28 Mar 2024 AMPE

Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript

Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript

09:41 28 Mar 2024 AMPE

Why Ampio Pharmaceuticals Stock Is Rising Today

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.

01:49 28 Mar 2024 AMPE

Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMPE Financial details

Company Rating
Neutral
Market Cap
1.39M
Income
-8.38M
Revenue
0
Book val./share
6.68
Cash/share
7.96
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.21
Forward P/E
-
PEG
0.05
P/S
-
P/B
0.33
P/C
0.11
P/FCF
-0.17
Quick Ratio
3.05
Current Ratio
3.37
Debt / Equity
0.07
LT Debt / Equity
-
-
-
EPS (TTM)
-11.01
EPS next Y
-
EPS next Q
1.58
EPS this Y
-40.18%
EPS next Y
-
EPS next 5Y
226.98%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-15.93%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-66.67%
Inst Own
194.99%
Inst Trans
0.97%
ROA
-110%
ROE
-106%
ROC
-1.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
832.02K
Shs Float
806.91K
-
-
-
-
Target Price
-
52W Range
1.5-8.2
52W High
-88.75%
52W Low
-10%
RSI
28
Rel Volume
0.19
Avg Volume
187.5K
Volume
35.31K
Perf Week
-44.44%
Perf Month
-46.43%
Perf Quarter
-69.49%
Perf Half Y
-77.27%
-
-
-
-
Beta
1.99
-
-
Volatility
0.42%, 0.33%
Prev Close
9.76%
Price
0.9
Change
13.92%

AMPE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
88.39-18.32-28.63-18.79-11.24
Operating cash flow per share
-31.57-32.45-25.56-21.21-28.04
Free cash flow per share
-33.04-32.5-25.67-21.35-28.04
Cash per share
19.7313.7830.1151.0216.79
Book value per share
13.6213.5930.3941.0715.64
Tangible book value per share
13.6213.5930.3941.0715.64
Share holders equity per share
13.6213.5930.3941.0715.64
Interest debt per share
-0.013.262.11.39-9.63
Market cap
44.98M82.48M274.83M113.6M3.47M
Enterprise value
37.4M77.42M258.69M80.63M-8.57M
P/E ratio
1.32-9.5-16.66-9.1-0.41
Price to sales ratio
00000
POCF ratio
-3.71-5.36-18.66-8.06-0.16
PFCF ratio
-3.54-5.35-18.58-8.01-0.16
P/B Ratio
8.5912.815.694.160.29
PTB ratio
8.5912.815.694.160.29
EV to sales
00000
Enterprise value over EBITDA
-0.68-3.49-18.42-3.350.37
EV to operating cash flow
-3.08-5.03-17.56-5.720.41
EV to free cash flow
-2.94-5.03-17.49-5.680.41
Earnings yield
0.76-0.11-0.06-0.11-2.44
Free cash flow yield
-0.28-0.19-0.05-0.12-6.09
Debt to equity
00.230.070.030.05
Debt to assets
00.10.050.020.05
Net debt to EBITDA
0.140.231.151.370.52
Current ratio
5.781.9310.086.9611.18
Interest coverage
2.23K-304.48003.08
Income quality
-0.361.130.930.831.29
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.05000.010
Capex to revenue
00000
Capex to depreciation
-0.44-0.02-0.05-0.090
Stock based compensation to revenue
00000
Graham number
164.5874.85139.94131.7862.88
ROIC
0.7-1.59-0.79-0.63-0.96
Return on tangible assets
2.42-0.62-0.72-0.32-0.62
Graham Net
-3.14-2.1621.2734.5614.4
Working capital
6.61M3.97M16.66M30.51M12.14M
Tangible asset value
5.24M6.44M17.51M27.28M11.79M
Net current asset value
-795.34K692K13.13M24.09M11.53M
Invested capital
00.230.070.030.05
Average receivables
0092.5K100.5K8K
Average payables
075.5K168.5K306.5K262K
Average inventory
00133K728.5K595.5K
Days sales outstanding
00000
Days payables outstanding
043.3357.63142.4617.03
Days of inventory on hand
0082.42397.360
Receivables turnover
00000
Payables turnover
08.426.332.5621.43
Inventory turnover
004.430.920
ROE
6.49-1.35-0.94-0.46-0.72
Capex per share
-1.47-0.05-0.11-0.150

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-8.61-2.79-4.87-1.82-1.53
Operating cash flow per share
-7.89-5.7-3.05-4.5-0.69
Free cash flow per share
-7.89-5.7-3.05-4.5-0.69
Cash per share
22.4916.7913.729.217.96
Book value per share
18.3815.6410.448.696.68
Tangible book value per share
18.3815.6410.448.696.68
Share holders equity per share
18.3815.6410.448.696.68
Interest debt per share
1.030.660.30.590.45
Market cap
13.57M3.47M3.47M3.47M2.93M
Enterprise value
-2.69M-8.57M-6.35M-3.03M-3.11M
P/E ratio
-0.52-0.41-0.24-0.63-0.6
Price to sales ratio
00000
POCF ratio
-2.28-0.81-1.51-1.02-5.27
PFCF ratio
-2.28-0.81-1.51-1.02-5.27
P/B Ratio
0.980.290.440.530.54
PTB ratio
0.980.290.440.530.54
EV to sales
00000
Enterprise value over EBITDA
0.582.961.531.942.22
EV to operating cash flow
0.4522.760.895.6
EV to free cash flow
0.4522.760.895.6
Earnings yield
-0.48-0.61-1.06-0.39-0.42
Free cash flow yield
-0.44-1.24-0.66-0.98-0.19
Debt to equity
0.050.050.070.070.07
Debt to assets
0.040.050.050.050.05
Net debt to EBITDA
3.534.162.364.174.31
Current ratio
4.6711.184.023.673.37
Interest coverage
-61.9126.7714.1300
Income quality
0.931.930.582.480.45
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
59.6831.3533.8218.8515.16
ROIC
-0.33-0.22-0.44-0.2-0.22
Return on tangible assets
-0.34-0.15-0.34-0.15-0.16
Graham Net
15.8714.49.937.676.05
Working capital
14.4M12.14M8.06M6.65M5.38M
Tangible asset value
13.85M11.79M7.88M6.56M5.38M
Net current asset value
13.33M11.53M7.88M6.56M5.38M
Invested capital
0.050.050.070.070.07
Average receivables
000690K955K
Average payables
468K157.5K336K601K543K
Average inventory
000389K732.5K
Days sales outstanding
00000
Days payables outstanding
28.623.66211.2200
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
3.153.80.4300
Inventory turnover
00000
ROE
-0.47-0.18-0.47-0.21-0.23
Capex per share
00000

AMPE Frequently Asked Questions

What is Ampio Pharmaceuticals, Inc. stock symbol ?

Ampio Pharmaceuticals, Inc. is a US stock , located in Englewood of Co and trading under the symbol AMPE

What is Ampio Pharmaceuticals, Inc. stock quote today ?

Ampio Pharmaceuticals, Inc. stock price is $0.9 today.

Is Ampio Pharmaceuticals, Inc. stock public?

Yes, Ampio Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap